Physician profile
Robert J Ishak
NPI 1295727790
$1,046.69
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $293 · 2021: $20.50 · 2022: $89.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $179.08 | 2019-2022 | |
| Novo Nordisk INC | $157.67 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $137.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $106.15 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.32 | 2019 | |
| Amgen INC. | $78.03 | 2019-2020 | |
| Amarin Pharma, INC. | $52.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.22 | 2019 | |
| Esperion Therapeutics, INC. | $40.33 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $38.88 | 2019-2020 | |
| Sanofi Pasteur INC. | $30.57 | 2019-2020 | |
| Allergan, INC. | $24.30 | 2019 | |
| Abbott Laboratories | $21.80 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.92 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ishak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.